These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension. Voswinckel R; Reichenberger F; Enke B; Kreckel A; Krick S; Gall H; Schermuly RT; Grimminger F; Rubin LJ; Olschewski H; Seeger W; Ghofrani HA Pulm Pharmacol Ther; 2008 Oct; 21(5):824-32. PubMed ID: 18657627 [TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension. Keogh AM; Jabbour A; Weintraub R; Brown K; Hayward CS; Macdonald PS J Heart Lung Transplant; 2007 Nov; 26(11):1079-83. PubMed ID: 18022071 [TBL] [Abstract][Full Text] [Related]
7. Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy. Bhatia S; Frantz RP; Severson CJ; Durst LA; McGoon MD Mayo Clin Proc; 2003 Oct; 78(10):1207-13. PubMed ID: 14531479 [TBL] [Abstract][Full Text] [Related]
8. Blood pressure control and sildenafil--carrot stick or sword of Damocles? Yao SS; Messerli FH Am J Cardiol; 2007 Aug; 100(3):552-3. PubMed ID: 17659945 [No Abstract] [Full Text] [Related]
9. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Lewis GD; Shah R; Shahzad K; Camuso JM; Pappagianopoulos PP; Hung J; Tawakol A; Gerszten RE; Systrom DM; Bloch KD; Semigran MJ Circulation; 2007 Oct; 116(14):1555-62. PubMed ID: 17785618 [TBL] [Abstract][Full Text] [Related]
10. Sildenafil reduces L-NAME-induced severe hypertension and worsening of myocardial ischaemia-reperfusion damage in the rat. Rossoni G; Manfredi B; De Gennaro Colonna V; Berti M; Guazzi M; Berti F Br J Pharmacol; 2007 Mar; 150(5):567-76. PubMed ID: 17245365 [TBL] [Abstract][Full Text] [Related]
11. Acute effects of sildenafil on exercise pulmonary hemodynamics and capacity in patients with COPD. Holverda S; Rietema H; Bogaard HJ; Westerhof N; Postmus PE; Boonstra A; Vonk-Noordegraaf A Pulm Pharmacol Ther; 2008; 21(3):558-64. PubMed ID: 18342559 [TBL] [Abstract][Full Text] [Related]
12. Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology. D'Alto M; Romeo E; Argiento P; Sarubbi B; Santoro G; Grimaldi N; Correra A; Scognamiglio G; Russo MG; Calabrò R Int J Cardiol; 2012 Mar; 155(3):378-82. PubMed ID: 21081251 [TBL] [Abstract][Full Text] [Related]
13. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Wilkins MR; Paul GA; Strange JW; Tunariu N; Gin-Sing W; Banya WA; Westwood MA; Stefanidis A; Ng LL; Pennell DJ; Mohiaddin RH; Nihoyannopoulos P; Gibbs JS Am J Respir Crit Care Med; 2005 Jun; 171(11):1292-7. PubMed ID: 15750042 [TBL] [Abstract][Full Text] [Related]
15. Impact of sildenafil therapy on pulmonary arterial hypertension in adults with congenital heart disease. Lu XL; Xiong CM; Shan GL; Zhu XY; Wu BX; Wu GH; Liu ZH; Ni XH; Cheng XS; Gu Q; Zhao ZH; Zhang DZ; Li WM; Zhang C; Tian HY; Guo YJ; Guo T; Liu HM; Zhang WJ; Gu H; Huang SA; Chen JY; Wu WF; Huang K; Li JJ; He JG Cardiovasc Ther; 2010 Dec; 28(6):350-5. PubMed ID: 20637015 [TBL] [Abstract][Full Text] [Related]
16. One year efficacy and safety of oral sildenafil treatment in severe pulmonary hypertension. Samarzija M; Zuljević E; Jakopović M; Sever B; Knezević A; Dumija Z; Vidjak V; Samija M Coll Antropol; 2009 Sep; 33(3):799-803. PubMed ID: 19860106 [TBL] [Abstract][Full Text] [Related]
17. Cardiovascular risk factors determine erectile and arterial function response to sildenafil. Solomon H; Wierzbicki AS; Lumb PJ; Lambert-Hammill M; Jackson G Am J Hypertens; 2006 Sep; 19(9):915-9. PubMed ID: 16942933 [TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension. Johnson RF; Loyd JE; Mullican AL; Fink CA; Robbins IM J Heart Lung Transplant; 2007 Apr; 26(4):363-9. PubMed ID: 17403478 [TBL] [Abstract][Full Text] [Related]
20. Therapy with sildenafil or bosentan decreases pulmonary vascular resistance in patients ineligible for heart transplantation because of severe pulmonary hypertension. Perez-Villa F; Farrero M; Sionis A; Castel A; Roig E J Heart Lung Transplant; 2010 Jul; 29(7):817-8. PubMed ID: 20363156 [No Abstract] [Full Text] [Related] [Next] [New Search]